Genor Biopharma Holdings Ltd

Edding Genor Group Holdings Limited, together with its subsidiaries, engages in the research, development, manufacturing, and distribution of biopharmaceutical products in China, the United States, and internationally. Its pipeline includes GB491, a differentiated CDK4/6 inhibitor for advanced or metastatic breast cancer; GB261, a novel CD3/CD20 bispecific antibody in Phase III clinical trials for autoimmune diseases; and GB263T and GB268, tri-specific antibody candidates in Phase I clinical trials. The company also provides Vancocin, Ceclor, Yirui Ping, Vascepa, Mulpleta, Jing Zhu Da, and Recormon, as well as three siRNA candidates for chronic disease treatment, entinostat, and lerociclib hydrochloride tablets. In addition, it is involved in marketing, commercialization, and trading of pharmaceutical products; research and development of respiratory products; and consultancy and promotion services. Its products are used in oncology, autoimmune, cardiovascular, respiratory, and anti-infective therapeutic areas. The company was founded in 2001 and is headquartered in Zhuhai, China.